Xcellon Biologics Bets Big on U.S. Biomanufacturing with Key Acquisition

BELTSVILLE, Md. – August 10, 2026 – In a move signaling a significant bet on domestic biotechnology infrastructure, Xcellon Biologics today announced its acquisition of a GMP biologics manufacturing facility from NextCure, Inc. The deal transforms the fledgling company, launched in 2025, into an end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) with the ambitious goal of accelerating the development of next-generation therapies on U.S. soil.

This acquisition equips Xcellon with a 40,000-square-foot facility featuring advanced capabilities, including two 1,000-liter single-use bioreactors and a dedicated bioconjugation suite. The company has appointed co-founder Abhishake Chhibber as Chief Executive Officer to lead its transformation. While the move positions Xcellon as a new, integrated player for biotech innovators, it also sheds light on the intense pressures facing clinical-stage companies and the broader strategic realignment occurring within the American biopharmaceutical landscape.

A Strategic Pivot Born from Financial Necessity

The availability of NextCure’s state-of-the-art facility is a story of strategic survival. The clinical-stage biopharmaceutical company has been navigating severe financial headwinds, reporting a net loss of $55.8 million for 2025 and watching its cash reserves dwindle to just $20.1 million by mid-2026. This financial reality forced a dramatic strategic reorientation.

In July, NextCure announced an all-stock merger with Avere Therapeutics, a move designed to secure its future by combining with a well-capitalized partner. As part of its restructuring to conserve capital ahead of the merger, NextCure began shedding non-essential assets. The sale of its manufacturing facility to Xcellon is a direct consequence of this pivot away from maintaining capital-intensive internal infrastructure. For NextCure, the divestment is a necessary step to streamline operations and focus resources on its core clinical programs. For Xcellon, it was a timely opportunity to acquire a turnkey manufacturing asset and leapfrog years of development.

Carving a Niche in a Crowded Field

Xcellon Biologics enters a competitive CRDMO market dominated by global giants like Lonza, Catalent, and WuXi Biologics. Rather than compete on scale, Xcellon’s strategy hinges on specialization. The company is focusing squarely on “bioconjugates and complex biologics,” a high-growth sector that includes sophisticated therapies like antibody-drug conjugates (ADCs). These therapies, which combine the targeting ability of an antibody with the cell-killing power of a potent drug, are notoriously difficult to develop and manufacture.

The global market for ADCs alone is projected to exceed $30 billion by 2028, driven by a wave of innovation in oncology and other therapeutic areas. Success in this field requires not just capacity, but deep, specialized expertise. By integrating antibody development, bioconjugation, and GMP manufacturing under one roof, Xcellon aims to provide a seamless, efficient pathway for biotech innovators.

“This acquisition represents far more than the expansion of our manufacturing capabilities,” said Abhishake Chhibber, Chief Executive Officer of Xcellon Biologics. “By integrating antibody development, bioconjugation development, analytical sciences, and GMP manufacturing within a single organization, we are creating a platform that enables innovators to move seamlessly from discovery through clinical supply.”

This integrated approach is a key differentiator. Biotech startups, often operating with lean teams and tight timelines, face significant logistical hurdles when managing multiple service providers. “By reducing handoffs between service providers and maintaining scientific continuity throughout development, we help clients advance complex biologics more efficiently,” noted Yuk Chiu, Chief Operating Officer of Xcellon Biologics. This promise of speed and streamlined project management is a powerful value proposition for a sector where time to clinic is paramount.

A Bet on America’s Biotech Backbone

Xcellon's expansion arrives at a critical juncture for U.S. industrial policy. The COVID-19 pandemic exposed profound vulnerabilities in global medical supply chains, sparking a national conversation about the need to bolster domestic manufacturing capacity. In response, the U.S. government has launched initiatives aimed at strengthening the nation’s biotechnology infrastructure and reducing reliance on overseas production.

Xcellon is positioning its growth as a direct contribution to this national imperative. The company’s mission extends beyond contract services to actively strengthening the domestic ecosystem, enabling therapies to be discovered, developed, and manufactured entirely within the United States.

“America has long been the global engine of biotechnology innovation,” Chhibber stated. “Our mission is to strengthen the development and manufacturing infrastructure that enables innovators to move seamlessly from discovery through clinical supply. By doing so, we aim to help ensure the United States remains the world’s leader in next-generation biologics and advanced biomanufacturing.”

This focus on a U.S.-based supply chain offers a strategic advantage, appealing to clients concerned with geopolitical risk and supply chain security. It also aligns the company with a powerful political and economic tailwind favoring domestic investment in critical industries.

Leadership for a New Chapter

Steering this ambitious vision falls to Abhishake Chhibber, a co-founder who now takes the helm as CEO. With nearly two decades of reported experience in corporate strategy, business development, and company building within the biotech industry, Chhibber is tasked with integrating the new facility and scaling the organization. His leadership will be crucial in navigating the operational complexities of transforming from a research-focused entity into a full-service manufacturing partner.

The challenge is significant: building a quality-centric culture, attracting and retaining specialized talent, and executing flawlessly for demanding clients in a regulated environment. Success will depend on the ability to deliver on the promise of an integrated, flexible, and reliable U.S.-based partner for the next wave of biologic drug development.

Xcellon expects the newly acquired facility to begin GMP operations in December 2026, marking the official launch of its integrated platform and a new chapter in its effort to reshape the landscape of American biomanufacturing.